Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Income Before Tax

Profit after all operating and non-operating items but before income tax.

Beta Bionics, Inc.NASDAQ: BBNX

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$21.9M, compared with -$28.66M a year earlier. Trailing-twelve-month income before tax was -$66.44M.

Context

  • Income before tax amounted to 73.0% of revenue in FY2025, down 11.1 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$21.9M or moves back toward the trailing-twelve-month quarterly average of -$16.61M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21.9M-62.6% QoQ
Last fiscal yearDec 2025
-$73.2M-33.7% YoY
LTMMar 2026
-$66.44M+6.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.6%——
1 year-33.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(73.2M) USD
Year-over-year change
-33.7%

Income Before Tax vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6.4% is the 5th highest of 7, against a peer median of +53.5%.
  • Income before tax amounts to 60.3% of revenue for BBNX, versus a peer median of 12.9%.
BBNX Competitors
Income Before Tax for BBNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 148.75B DKK+5.7%+23.6%45.2%
DXCMDexCom, Inc.LTM Jun 2026$1.28B USD+63.2%+40.7%25.8%
PODDInsulet CorporationLTM Jun 2026$494.7M USD+82.7%+226.0%16.2%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$131.82M USD+637.8%——
MNKDMannKind CorporationLTM Mar 2026-$28.58M USD-186.0%—7.9%
BBNXBeta Bionics, Inc.LTM Mar 2026-$66.44M USD+6.4%—60.3%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026-$98.06M USD+43.8%—9.5%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026-$197M USD——6.1%
Peer median (excluding BBNX) —+53.5%+40.7%12.9%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue179K12M65.12M100.25M
Cost of Revenue05.69M29.24M44.71M
Gross Profit179K6.31M35.89M55.54M
Gross Margin100.0%52.6%55.1%55.4%
Research & Development31.43M17.94M26.18M34.79M
Selling, General & Admin33.5M24.22M54.96M92.43M
Operating Expenses66.02M42.16M81.14M127.22M
Depreciation & Amortization1.35M1.23M1.15M2.88M
EBITDA(63.4M)(42.87M)(53.61M)(70.32M)
EBITDA Margin-35418.4%-357.4%-82.3%-70.1%
Operating Income(65.84M)(35.85M)(45.25M)(71.68M)
Operating Margin-36784.4%-298.9%-69.5%-71.5%
Interest Income196K1.78M3.91M10.93M
Interest Expense14K000
Other Income / Expenses1.09M(8.25M)(9.51M)(1.52M)
Income Before Tax(64.75M)(44.1M)(54.76M)(73.2M)
Pre-Tax Margin-36173.7%-367.6%-84.1%-73.0%
Income Tax Expense0001K
Net Income(64.75M)(44.1M)(54.76M)(73.2M)
Net Margin-36173.7%-367.6%-84.1%-73.0%
EPS (Basic)(12.96)(8.31)(8.60)(1.81)
EPS (Diluted)(12.96)(8.31)(8.60)(1.81)
Weighted Avg Shares5M5.3M6.37M40.53M
Weighted Avg Shares (Diluted)5M5.3M6.37M40.53M

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.